Vitamin D is involved in many biological processes.
The role of vitamin D in patients with hepatocellular carcinoma (HCC) remains inconclusive, although there is evolving evidence that vitamin D may modulate cancer development and progression.
Dr Waidmann and colleagues from Germany evaluated serum vitamin D as prognostic parameter in HCC.
The team performed a prospective cohort study.
HCC patients were prospectively recruited and 25-hydroxyvitamin D3 (25(OH)D3) levels were determined.
25(OH)D3 levels were compared to stages of cirrhosis and HCC stages with nonparametric Kruskal–Wallis tests and Spearman correlations in 200 HCC patients.
The association of the 25(OH)D3 levels, and overall survival was assessed in uni- and multivariate Cox regression models.
|Patients with severe 25(OH)D3 deficiency had the highest mortality risk |
|Alimentary Pharmacology & Therapeutics|
The researchers evaluated 200 patients with HCC.
The mean follow-up time was 322 days with a range of 1–1508 days.
The team noted that 19 patients underwent liver transplantation, and 60 patients died within the observation time.
The mean serum 25(OH)D3 concentration was 17 ng/mL with a range of 1–72 ng/mL.
The researchers found that 25(OH)D3 serum levels negatively correlated with the stage of cirrhosis as well as with stages of HCC.
Patients with severe 25(OH)D3 deficiency had the highest mortality risk.
Furthermore, very low 25(OH)D3 levels were associated with mortality independently from the MELD score and high alpha-Fetoprotein levels in a multivariate Cox regression model.
Dr Waidmann's team concludes, "We conclude that 25(OH)D3 deficiency is associated with advanced stages of hepatocellular carcinoma and it is a prognostic indicator for a poor outcome."